Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: A series of 15 cases To the Editor: Treatment of papulopustular rosacea (PPR) and periorificial dermatitis (POD) can be challenging in children. Demodex mites, although part of the normal-appearing skin fauna, are more numerous in rosacea and POD than in normal-appearing skin. 1 In 2014, we reported a case of severe oculocutaneous rosacea in a 12-year-old girl treated with a single dose of oral ivermectin 2 ; the excellent response encouraged us to use it in subsequent cases.
The aim of this retrospective study was to assess the benefit and tolerability of oral and topical ivermectin therapy in pediatric PPR and POD.
Eight patients with PPR and 7 with POD (mean age 9.8 6 2.2 years) were treated with either a single dose of 200 to 250 g/kg of oral ivermectin or a compound of 1% ivermectin in an oil-inwater base cream applied once a day for 3 months. Oral ivermectin was prescribed for 6 children with PPR and 3 with POD. Oral or topical therapy was chosen depending on the severity of the condition. No other medications were allowed.
To assess disease severity at baseline and after treatment, we applied the Investigator Global Assessment score by retrospectively reviewing clinical charts and photographs. We rated overall severity on a 0-to-4 scale as 0 ¼ clear, 1 ¼ almost clear, 2 ¼ mild, 3 ¼ moderate, and 4 ¼ severe. We considered treatment to be successful when lesions cleared or almost cleared. Recurrence was documented when a disease flare required a further course of therapy. Table I summarizes the demographic and clinical data. Complete or almost complete clearance (Investigator Global Assessment score 0-1) was achieved in 8 patients treated orally and in 6 children treated with topical ivermectin. One patient did not improve after oral therapy. The overall response to topical or oral ivermectin was excellent: 14 of 15 (93%) patients achieved complete or almost complete clearance of lesions (Fig 1) ; 3 of 14 patients experienced relapses (21%) and 11 of 14 remained disease-free for a prolonged period. Mean follow-up was 11.9 6 7.1 (range 2-42) months. The only adverse event observed was mild, transient desquamation of the affected skin in 3 patients receiving oral ivermectin and in 2 patients using topical ivermectin.
In 2014, the US Food and Drug Administration approved 1% ivermectin cream for treatment of rosacea in adults. Oral ivermectin is licensed for treatment of filariasis in children weighing more than 15 kg and has been used off-label in refractory cases of rosacea. 2, 3 Topical ivermectin may produce a burning sensation, pruritus, and dry skin in 0.7% to 1.8% of patients. 4 The only adverse event in our series was transient, mild desquamation in 5 patients. This was observed in patients receiving either topical or oral therapy. We hypothesize the desquamation may be a result of a Mazzotti-like reaction resulting from an immunologic reaction to dying mites, as observed in systemic parasitoses after ivermectin therapy. In conclusion, both oral and topical ivermectin We categorized dermatologist density as ''none'' (counties with no dermatologists), ''low'' (0.1-11 dermatologists/100,000), ''intermediate-low'' (11.1-32 dermatologists/100,000), ''intermediate-high'' (32.1-82 dermatologists/100,000), and ''high'' (82.1-422 dermatologists/100,000). County status included metropolitan, nonmetropolitan, or urban counties. Tumor stage was derived from the American Joint Committee on Cancer (AJCC) stage, 6th edition, 4 and was categorized as ''early'' (I/II) and ''advanced'' (III/IV).
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We used 2 and analysis of variance to calculate univariate differences. Overall survival analysis was conducted using Kaplan-Meier method with log-rank statistic and Cox proportional hazards modeling. The data were analyzed using statistical software (SPSS, Version 23.0, IBM Corp, Armonk, NY).
We examined 2709 patients with MCC. Increased dermatologist density was significantly associated with better overall survival for patients with MCC (P ¼ .048). Higher median household income, metropolitan status, and increased density of primary care physicians and hospitals with oncologists were also associated with increased dermatologist density. Tumor stage did not significantly differ with regard to dermatologist density (Table I) .
In (Table II) .
Our results demonstrate that patients with MCC living in areas of intermediate-low or high dermatologist density have improved survival when compared with patients living in areas of no dermatologists. Interestingly, there was no significant difference in survival for patients living in areas of intermediate-high dermatologist density. Importantly, median household income, county status, and access to both primary care physicians and oncologists were not associated with survival, supporting the critical role of dermatologists in MCC survival.
Paradoxically, our analysis did not reveal an association between dermatologist density and tumor stage at diagnosis, however we interpret these results with caution. AJCC 6th edition, 4 over 7th edition, 5 staging was used as it was available for far more cases. The AJCC 6th edition groups MCC with cutaneous squamous carcinoma and 80 other cutaneous neoplasms and thus may not be an adequate gauge of disease severity. 6 Limitations of this study include an information bias because of the use of registry and census tract data. Further studies are necessary to confirm and further explore this association. 
